Breast Cancer

Erika P. Hamilton, MD, discusses the potential integration of novel selective estrogen receptor degraders into the treatment armamentarium for ER-positive, HER2-negative breast cancer.

Denise A. Yardley, MD, discusses the efficacy achieved with ribociclib plus letrozole in patients with hormone receptor–positive, HER2-negative advanced breast cancer.

Experts discuss the optimal monitoring of patients to identify interstitial lung disease early and how to intervene.

A brief review of the full spectrum of risk factors that impact the likelihood of interstitial lung disease.

Sara A. Hurvitz, MD, discusses the rationale for the phase 2 coopERA Breast Cancer trial in estrogen receptor–positive, HER2-negative breast cancer.

Updated overall survival data from the phase 3 MONALEESA-3 trial demonstrated a sustained benefit with the addition of ribociclib to fulvestrant in patients with hormone receptor–positive, HER2-negative advanced breast cancer, and provide further evidence that this is a feasible approach for frontline therapy in this population.

Early-stage hormone receptor–positive, HER2-negative breast cancer is generally associated with a good prognosis; however, even with early intervention, some patients recur and have reduced survival.

Maryam Lustberg, MD, MPH, discusses ongoing research in breast cancer.

Andrea L. Silber, MD, discusses the importance of improving clinical trial inclusivity in breast cancer.

Martine Extermann, MD, PhD, discusses the significance of novel treatment options in HER2-positive breast cancer.

Hope S. Rugo, MD, discusses the final data from the phase 3 KEYNOTE-355 trial with pembrolizumab plus chemotherapy in patients with metastatic TNBC and the clinical impact on the treatment paradigm.

Nadia Harbeck, MD, PhD, discusses the key results from the phase 2 WSG ADAPT-TP trial in patients with HER2-positive, hormone receptor–positive early-stage breast cancer.

Zahi Mitri, MD, MS, discusses developments in the treatment of patients with HER2-positive breast cancer.

Comprehensive insight on the symptomology of interstitial lung disease, followed by tools and methods that can aid in accurate diagnosis.

Joyce A. O’Shaughnessy, MD, provides an overview of interstitial lung disease, considering both causes and possible risk factors.

Dawn Hershman, MD, a leading breast cancer physician-scientist and pioneer in the burgeoning field of cancer care delivery research, has been named to the Giants of Cancer Care Class of 2021.

Mark D. Pegram, MD, discusses unmet clinical needs in HER2-positive metastatic breast cancer.

Take-home messages regarding the optimal identification and management of ILD in breast cancer through the lens of multidisciplinary care.

Drawing from personal experience, experts provide practical advice on identifying and treating interstitial lung disease in patients with breast cancer during the era of COVID-19.

Giredestrant resulted in a greater relative reduction in Ki67 score from baseline to week 2 of a window of opportunity phase vs anastrozole in patients with estrogen receptor–positive, HER2-negative early breast cancer, according to results from an interim analysis of the phase 2 coopERA Breast Cancer trial.

Personalized medicine has come to the forefront of breast cancer management, with genomic tools being utilized to avoid unnecessary chemotherapy in those with early-stage disease, PARP and PI3K inhibitors improving outcomes for those who harbor select mutations, and the emergence of highly active targeted agents shaking up the HER2-positive paradigm.

Baseline tumor immunogenicity may be associated with higher pathologic complete response rates and favorable outcomes in hormone receptor-positive, HER2-positive early stage breast cancer when comparing de-escalated neoadjuvant ado-trastuzumab emtansine with or without endocrine therapy, vs trastuzumab plus endocrine therapy.

Hope S. Rugo, MD, discusses the overall survival data with first-line pembrolizumab plus chemotherapy as a treatment for patients with metastatic triple-negative breast cancer, as reported in the phase 3 KEYNOTE-355 trial.

The combination of ribociclib and letrozole demonstrated a statistically significant and clinically meaningful overall survival benefit compared with letrozole alone in the first-line setting for postmenopausal patients with hormone receptor–positive, HER2-negative advanced breast cancer, according to results from the phase 3 MONALEESA-2 trial.

Fam-trastuzumab deruxtecan-nxki demonstrated a clinically meaningful and statistically significant improvement in progression-free survival vs standard of care trastuzumab emtansine for patients with previously treated HER2-positive metastatic breast cancer.